Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Transcriptional Dependencies in Diffuse Intrinsic Pontine Glioma
Surya Nagaraja, Nicholas A. Vitanza, Pamelyn J. Woo, et al.
Cancer Cell (2017) Vol. 31, Iss. 5, pp. 635-652.e6
Open Access | Times Cited: 345

Showing 1-25 of 345 citing articles:

c-Jun overexpression in CAR T cells induces exhaustion resistance
Rachel C. Lynn, Evan W. Weber, Elena Sotillo, et al.
Nature (2019) Vol. 576, Iss. 7786, pp. 293-300
Open Access | Times Cited: 661
Epigenetics in Health and Disease
Lian Zhang, Qianjin Lu, Christopher Chang
Advances in experimental medicine and biology (2020), pp. 3-55
Closed Access | Times Cited: 509
Targeting neuronal activity-regulated neuroligin-3 dependency in high-grade glioma
Humsa S. Venkatesh, Lydia Tam, Pamelyn J. Woo, et al.
Nature (2017) Vol. 549, Iss. 7673, pp. 533-537
Open Access | Times Cited: 438
Glioblastoma stem cells: lessons from the tumor hierarchy in a lethal cancer
Ryan C. Gimple, Shruti Bhargava, Deobrat Dixit, et al.
Genes & Development (2019) Vol. 33, Iss. 11-12, pp. 591-609
Open Access | Times Cited: 428
Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M+ diffuse midline gliomas
Christopher Mount, Robbie G. Majzner, Shree Sundaresh, et al.
Nature Medicine (2018) Vol. 24, Iss. 5, pp. 572-579
Open Access | Times Cited: 417
Diffuse Glioma Heterogeneity and Its Therapeutic Implications
James Nicholson, Howard A. Fine
Cancer Discovery (2021) Vol. 11, Iss. 3, pp. 575-590
Open Access | Times Cited: 314
PRC2 is high maintenance
Jia-Ray Yu, Chul‐Hwan Lee, Ozgur Oksuz, et al.
Genes & Development (2019) Vol. 33, Iss. 15-16, pp. 903-935
Open Access | Times Cited: 234
The Glioma Stem Cell Model in the Era of Single-Cell Genomics
Mario L. Suvà, Itay Tirosh
Cancer Cell (2020) Vol. 37, Iss. 5, pp. 630-636
Open Access | Times Cited: 234
CDK inhibitors in cancer therapy, an overview of recent development.
Mengna Zhang, Lingxian Zhang, Ruoxuan Hei, et al.
PubMed (2021) Vol. 11, Iss. 5, pp. 1913-1935
Closed Access | Times Cited: 224
Targeting Epigenetic Crosstalk as a Therapeutic Strategy for EZH2-Aberrant Solid Tumors
Xun Huang, Juan Yan, Min Zhang, et al.
Cell (2018) Vol. 175, Iss. 1, pp. 186-199.e19
Open Access | Times Cited: 216
Pervasive H3K27 Acetylation Leads to ERV Expression and a Therapeutic Vulnerability in H3K27M Gliomas
Brian Krug, Nicolas Jay, Ashot S. Harutyunyan, et al.
Cancer Cell (2019) Vol. 35, Iss. 5, pp. 782-797.e8
Open Access | Times Cited: 184
Neural Precursor-Derived Pleiotrophin Mediates Subventricular Zone Invasion by Glioma
Elizabeth Y. Qin, Dominique D. Cooper, Keene L. Abbott, et al.
Cell (2017) Vol. 170, Iss. 5, pp. 845-859.e19
Open Access | Times Cited: 181
Developmental origins and emerging therapeutic opportunities for childhood cancer
Mariella G. Filbin, Michelle Monje
Nature Medicine (2019) Vol. 25, Iss. 3, pp. 367-376
Open Access | Times Cited: 176
Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening
Grant L. Lin, Kelli M. Wilson, Michele Ceribelli, et al.
Science Translational Medicine (2019) Vol. 11, Iss. 519
Open Access | Times Cited: 175
Histone Variant and Cell Context Determine H3K27M Reprogramming of the Enhancer Landscape and Oncogenic State
Surya Nagaraja, Michael A. Quezada, Shawn Gillespie, et al.
Molecular Cell (2019) Vol. 76, Iss. 6, pp. 965-980.e12
Open Access | Times Cited: 161
Re-programing Chromatin with a Bifunctional LSD1/HDAC Inhibitor Induces Therapeutic Differentiation in DIPG
Jamie N. Anastas, Barry M. Zee, Jay H. Kalin, et al.
Cancer Cell (2019) Vol. 36, Iss. 5, pp. 528-544.e10
Open Access | Times Cited: 160
CDK7 inhibitors as anticancer drugs
Georgina P. Sava, Hailing Fan, R. Charles Coombes, et al.
Cancer and Metastasis Reviews (2020) Vol. 39, Iss. 3, pp. 805-823
Open Access | Times Cited: 154
HDAC inhibitors elicit metabolic reprogramming by targeting super-enhancers in glioblastoma models
Trang Nguyen, Yiru Zhang, Enyuan Shang, et al.
Journal of Clinical Investigation (2020) Vol. 130, Iss. 7, pp. 3699-3716
Open Access | Times Cited: 150
The neuroscience of cancer
Rebecca Mancusi, Michelle Monje
Nature (2023) Vol. 618, Iss. 7965, pp. 467-479
Closed Access | Times Cited: 120
Cancers make their own luck: theories of cancer origins
Amir Jassim, Eric P. Rahrmann, Benjamin D. Simons, et al.
Nature reviews. Cancer (2023) Vol. 23, Iss. 10, pp. 710-724
Open Access | Times Cited: 118
Glioma
Michael Weller, Patrick Y. Wen, Susan M. Chang, et al.
Nature Reviews Disease Primers (2024) Vol. 10, Iss. 1
Closed Access | Times Cited: 113
Glioma synapses recruit mechanisms of adaptive plasticity
Kathryn R. Taylor, Tara Barron, Alexa Hui, et al.
Nature (2023) Vol. 623, Iss. 7986, pp. 366-374
Open Access | Times Cited: 94
Remote neuronal activity drives glioma progression through SEMA4F
Emmet Huang-Hobbs, Yi-Ting Cheng, Yeunjung Ko, et al.
Nature (2023) Vol. 619, Iss. 7971, pp. 844-850
Closed Access | Times Cited: 81
Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Sriram Venneti, Abed Rahman Kawakibi, Sunjong Ji, et al.
Cancer Discovery (2023) Vol. 13, Iss. 11, pp. 2370-2393
Open Access | Times Cited: 79
Spatially controlled construction of assembloids using bioprinting
Julien G. Roth, Lucia G. Brunel, Michelle S. Huang, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 63
Page 1 - Next Page

Scroll to top